Microbiota I-Center (MagIC) (香港微生物菌群創新中心)’s Post

🔬 In our latest review, we have systematically reported the therapeutic potentials of Verbascoside and its various formulations, along with their respective therapeutic uses. 🌿Verbascoside, a polyphenolic compound from the class of phenylethanoid glycosides, is abundantly found among 200 species of 23 families of plants. This compound has gained recent attention due to its wide-spectrum therapeutic properties, including antioxidant, antimicrobial, anti-inflammatory, neuroprotective, cardioprotective, skin-protective, and anti-cancer benefits. Congratulations to the scholars @Rajdeep Saha, ANKIT MAJIE, and Ritika Baidya from my research team Group Polyphenol-BIT for collating extensive information and publishing this work. Take a look at our article to delve deeper into the exciting world of Verbascoside and its therapeutic applications: https://lnkd.in/gKHg3xDs #Verbascoside #Polyphenols #Inflammation #Antioxidant #Formulations #NaturalProductResearch #Phytochemicals #Pharmacology

Revolutionize Your Rheumatoid Arthritis Research! Discover how Central BioHub’s high-quality biospecimen can enhance your autoimmune and rheumatoid arthritis (RA) studies! We provide serum, plasma and urine samples that are tested for common RA specific lab parameters like anti-CCP, RF, CRP, ESR and others, ensuring they meet the rigorous demands of your research. Sample Specifications 🧪 – ·     Matrix: Serum, Plasma, Urine ·     Lab Parameter: anti-Cyclic citrullinated peptide (CCP) / anti-Citrullinated protein antibodies (ACPA) | Rheumatoid factor (RF) | C-reactive protein (CRP) | Erythrocyte sedimentation rate (ESR) | ·     ICD-10: M05. + | M06. + Explore our online marketplace and discover how Central BioHub's Rheumatoid Arthritis samples can make a difference. ·     https://lnkd.in/eGwyE-PX #ResearchAndDevelopment #Biobanking #Diagnostics #Onlinemarketplace #DrugDiscovery #BiomedicalResearch #ClinicalResearch #IVD #Biotechnology #Healthcare #Pharma #Biomedicine

𝐏𝐫𝐨𝐭𝐡𝐫𝐨𝐦𝐛𝐢𝐧 𝐂𝐨𝐦𝐩𝐥𝐞𝐱 𝐂𝐨𝐧𝐜𝐞𝐧𝐭𝐫𝐚𝐭𝐞 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐆𝐥𝐨𝐛𝐚𝐥 𝐒𝐢𝐳𝐞, 𝐒𝐡𝐚𝐫𝐞 & 𝐅𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝟐𝟎𝟑𝟒 ▶𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅: https://lnkd.in/dra-yg_Y The Prothrombin Complex Concentrate (PCC) market, valued at USD 727.5 million in 2021, is anticipated to grow significantly, reaching USD 2153.2 million by 2032 with a CAGR of 10.4%. PCC, also known as factor IX complex, is derived from human plasma and contains concentrated clotting factors like II, IX, and X, with some variants including factor VII. It is used primarily to treat bleeding disorders such as haemophilia B and coagulation factor deficiencies induced by treatments like warfarin. Administered intravenously via syringe, PCC replenishes clotting factors rapidly without the need for blood typing or thawing, offering clinical advantages over fresh frozen plasma (FPP). These advantages, coupled with relaxed regulatory environments, are expected to drive market growth by enhancing efficiency and meeting increasing demand for effective clotting treatments. 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧: ▶𝐁𝐲 𝐏𝐫𝐨𝐝𝐮𝐜𝐭 𝐓𝐲𝐩𝐞: Laboratory Temperature Controllers, Laboratory Thermostats, Laboratory Chillers, Laboratory Circulators, Others. ▶𝐁𝐲 𝐌𝐨𝐝𝐚𝐥𝐢𝐭𝐲 𝐓𝐲𝐩𝐞: Standalone/ benchtop, Portable/ handheld. ▶𝐁𝐲 𝐄𝐧𝐝 𝐔𝐬𝐞𝐫: Hospitals, Pharma & biotech Industry, Chemical Industry, Food & Beverage Industry, Others.             ▶𝐁𝐲 𝐑𝐞𝐠𝐢𝐨𝐧: North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA).   𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐜𝐨𝐯𝐞𝐫𝐞𝐝: Octapharma, Grifols, Novo Nordisk, CSL Behring B.V., Kedrion Biopharma, China Biologic Products Holdings Inc, Shire Leasing PLC, Sanquin. #PCC #BloodClotting #Hemophilia #Coagulation #Thrombosis #FactorIX #VitaminK #BleedingDisorders #AnticoagulantReversal #Warfarin #Hemostasis #FactorVIII #DIC #FactorX #Fibrinogen #Hematology #TraumaCare #CriticalCare #Pharmaceuticals #MedicalResearch

Aqneursa (levacetylleucine, N-acetyl-L-leucine) and Miplyffa (arimoclomol, https://lnkd.in/gTJDd5z9) are now FDA-approved treatments for Niemann-Pick disease type C (NPC), marking a significant advancement in addressing this rare inherited lysosomal disorder, with approvals occurring within a week of each other. IntraBio Inc's Aqneursa, approved on September 24, 2024, is indicated for treating neurological symptoms associated with NPC in adults and pediatric patients weighing at least 15 kilograms. Notably, Aqneursa has been approved as a standalone therapy, while Zevra Therapeutics' Miplyffa requires co-administration with the enzyme inhibitor miglustat. Miplyffa was assessed in a pivotal trial (CT-ORZY-NPC-002, NCT02612129, https://lnkd.in/gYjBv27M) over 12 months, whereas Aqneursa's significant benefits were observed as early as 12 weeks in its pivotal trial (IB1001-301, NCT05163288, https://lnkd.in/gAbhs7HT). The acetylation of leucine to form N-acetyl-L-leucine (levacetylleucine) facilitates its uptake through organic anion transporters (OAT1 and OAT3) and the monocarboxylate transporter (MCT1), enhancing cellular distribution. Levacetylleucine is metabolized into acetate and L-leucine by widely expressed enzymes; notably, cytochrome P450 enzymes are not involved in its metabolism. Aqneursa (levacetylleucine) is protected under U.S. Patent 11,400,067, with a patent expiration date of August 11, 2037. The patent's inventor is IntraBio's scientific founder, Michael Strupp. #Arimoclomol #Miplyffa #Zevra #NPC #Levacettlleucine #Aqneursa #IntraBio

🔬 Unlocking the Future of Lupus Nephritis Treatment: A New Report by Maximize Market Research Pvt. Ltd. 🔬 We're thrilled to share the latest insights from our comprehensive research report on the Lupus Nephritis Market! 🌍💡 📈 Market Growth: The Lupus Nephritis market was valued at USD 2.02 billion in 2023 and is projected to soar to USD 3.21 billion by 2030, driven by a robust CAGR of 6.8%. This growth underscores the increasing need for advanced treatments for this serious kidney complication caused by systemic lupus erythematosus (SLE). Sample Report Link :https://lnkd.in/dr_6EwDB 💊 Innovative Treatments: Key treatments include corticosteroids, immunosuppressants, and emerging biologics. Notably, AstraZeneca's Saphnelo and new therapies like low-dose intravenous cyclophosphamide are making strides in reducing symptoms and improving patient outcomes. 🌐 Global Market Dynamics: North America and Europe lead the market due to high prevalence and advanced healthcare infrastructure. Asia Pacific is emerging rapidly, fueled by large populations and significant R&D investments, particularly in India and China. Middle East & Africa and South America are developing markets with growing awareness and investment in healthcare infrastructure. 🔬 Market Drivers: Increasing Prevalence: With millions affected worldwide, the demand for effective treatments is escalating. Technological Advancements: Innovations in precision medicine and new drug development are transforming patient care. Government Investments: Enhanced funding for healthcare infrastructure and research is propelling market growth. 🚀 Opportunities and Challenges: Opportunities: Growing clinical trials, new drug launches, and heightened global awareness create vast opportunities for both new entrants and established players. Challenges: Identifying the right patients, managing long-term treatments, and addressing significant side effects of current therapies remain critical hurdles. Lupus Nephritis Market, Key Players are 1. AstraZeneca - UK 2. Aurinia Pharmaceuticals - Canada 3. Biogen - USA 4. Bristol Myers Squibb - USA 5. ChemoCentryx - USA #LupusNephritis #HealthcareInnovation #Pharmaceuticals #Samurai #Colin #billie #Biologics #ClinicalTrials #GlobalHealthcare

Exciting News for Rheumatoid Arthritis Researchers! 🚀 Are you on the cutting edge of #RheumatoidArthritis research? Look no further! #CentralBioHub is revolutionizing access to high-quality RA biospecimens. 🧬 From serum, plasma, to urine samples, we have got you covered with meticulously collected specimens. Our samples are tested for-CCP, RF, CRP, ESR, and more lab parameters, ensuring they meet the rigorous demands of your research. Sample Specifications 🧪 – ·     Matrix: Serum, Plasma, Urine ·     Lab Parameter: anti-Cyclic citrullinated peptide (CCP) / anti-Citrullinated protein antibodies (ACPA) | Rheumatoid factor (RF) | C-reactive protein (CRP) | Erythrocyte sedimentation rate (ESR)  ·     ICD-10: M05. + | M06. + Explore our online marketplace and discover how Central BioHub's Rheumatoid Arthritis samples can make a difference. · https://lnkd.in/eGwyE-PX #ResearchAndDevelopment #Biobanking #Diagnostics #Onlinemarketplace #DrugDiscovery #BiomedicalResearch #ClinicalResearch #IVD #Biotechnology #Healthcare #Pharma #Biomedicine

Genetic variability profoundly impacts drug response, influencing treatment efficacy and safety. It alter drug target structures, affecting receptor and enzyme function, which in turn, modifies drug efficacy. Understanding these variations enables tailored treatments, optimizing patient outcomes. It can alter enzyme activity, impacting drug metabolism and activation, guiding dosage adjustments. Variations in transporter proteins affect drug distribution within the body, impacting treatment effectiveness. Identifying genetic mutations influencing drug targets is critical in overcoming drug resistance, especially in antimicrobial and oncological therapies. Submissions are open for the upcoming issue. You may submit case reports, case studies, and research or review papers. Submit to: editor.geneticsandheredity@journalmaples.org Follow our page: https://lnkd.in/dd-AwMD8 Visit us: https://lnkd.in/dhyieEcT (Source: internet) #Pharmacogenomics #PersonalizedMedicine #Genetic #Drugmetabolism 

🔬 Just co-authored an article on EUDRACAP® Select as a delivery system for a proprietary microbiome! 🦠💊 Imagine these capsules as tiny shuttles for your biologicals, precisely delivering them to the right target. 🚀👾 Check out how it works in this article!

Human genomes contain around 30,000 genes, which encode functional and structural proteins. Among these, a small number are pharmacogenomic proteins, important for safe and effective medication therapy. Testing individual’s genetics for these proteins can improve drug therapy by affecting metabolizing enzymes, targets, receptors, and transporters. This enables healthcare providers to practice more efficiently and precisely and help people to reach optimal drug therapy. #pharmacogenomics #pgx #optimal_drug_therapy #medicine